A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Moderate to Severe Atopic Dermatitis Clinical Trial

Official title:
A RANDOMIZED, DOUBLE-BLIND, DOSE-ESCALATION, PLACEBO-CONTROLLED PHASE I CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Status Not yet recruiting

Clinical Trial Summary

The study will be conducted to evaluate the safety and tolerability of SHR-1819 injection and describe the PK/PD/ADA and explore the clinical efficacy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Dermatitis
Dermatitis, Atopic
Eczema
Moderate to Severe Atopic Dermatitis

Clinical Trial Details

NCT number	NCT05197023
Study type	Interventional
Source	Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact	JianHui Li, medical director
Phone	86-0518-82342973
Email	jianhui.li@hengrui.com
Status	Not yet recruiting
Phase	Phase 1
Start date	January 2022
Completion date	June 8, 2022

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06012812` - A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis	Phase 2
Completed	`NCT05549947` - Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis	Phase 2
Recruiting	`NCT06136741` - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis	Phase 2
Recruiting	`NCT06099704` - Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
Completed	`NCT03568162` - Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis	Phase 2
Completed	`NCT00148746` - Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis	N/A
Recruiting	`NCT05702268` - Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis	Phase 2
Recruiting	`NCT05997927` - Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis	Phase 2
Not yet recruiting	`NCT06239311` - Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.	Phase 3
Terminated	`NCT01286220` - Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis	N/A
Completed	`NCT02426359` - Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients	Phase 2